Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.

Cancer immunology, immunotherapy : CII - 1 May 2022

Zhou Bolun, Gao Shugeng

Abstract excerpt

Lung adenocarcinoma (LUAD), the most common type of cancer, is hard to diagnose and has an unfavorable prognosis. Tumor mutation burden (TMB) is a useful predictor and can also determine the efficacy of immunotherapy in various cancers. The present study focused on unraveling the association between immune infiltration and TMB and developing an immune- and TMB-related prognostic model to predict LUAD patients'...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Biomarkers, Tumor
Share to Gene Expression Regulation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Prognosis

Source

Open in PubMed Open full text

Identifiers

PMID: 34635925
DOI: 10.1007/s00262-021-03066-4
PMCID: PMC10992114

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Construction and validation of a novel immune and tumor mutation burden-based prognostic model in lung adenocarcinoma.PMID 34635925Read ↗

Exploration of Tumor Mutation Burden Combined with Immune Infiltrates in the Prognosis of Lung AdenocarcinomaSemantic proximity Read ↗

Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.Semantic proximity Read ↗

An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.Semantic proximity Read ↗

A new immune signature for survival prediction and immune checkpoint molecules in lung adenocarcinoma.Semantic proximity Read ↗

Clinical and Prognostic Implications of an Immune-Related Risk Model Based on TP53 Status in Lung AdenocarcinomaSemantic proximity Read ↗

Identification of lung adenocarcinoma subtypes and predictive signature for prognosis, immune features, and immunotherapy based on immune checkpoint genesSemantic proximity Read ↗

Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.Semantic proximity Read ↗

CD8+ T Cell-Associated Gene Signature Correlates With Prognosis Risk and Immunotherapy Response in Patients With Lung AdenocarcinomaSemantic proximity Read ↗

Systematic construction and validation of an immune prognostic model for lung adenocarcinomaSemantic proximity Read ↗

Construction of a novel prognostic model for evaluation of immune infiltration and immunotherapy in lung adenocarcinomaSemantic proximity Read ↗

Identification of an immune signature predicting prognosis risk of patients in lung adenocarcinomaSemantic proximity Read ↗

Identification of mutational signature for lung adenocarcinoma prognosis and immunotherapy prediction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.